Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Irulya Therapeutics Inc Is Committed To Transforming The Lives Of Patients With Serious, Underserved Diseases By Developing Disease-Modifying Therapies. The Company Is Currently Developing Lam-001 For The Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease (Ph-Ild), Bronchiolitis Obliterans Syndrome Post-Lung Transplant (Bos), And Sarcoidosis-Associated Pulmonary Hypertension (Saph). A Phase 2a Study In Ph Patients Has Been Completed; A Phase 2 Clinical Study In Bos Patients Is Ongoing; A Phase 2b Clinical Study In Ph-Ild Is Ongoing; And A Phase 2 Clinical Study In Saph Is Ongoing.